IBM’s Record Rout Leaves a Technical Bounce, But the Real Test Lies in Those Delayed Deals
Published on 07/25/2026 at 03:21 | Redaktion boerse-global.de
The worst single-day sell-off in IBM’s history has given way to a tentative recovery, but the relief rally that lifted shares nearly 3.7% in German trading on Friday to €188.38 is drawing sharp skepticism from market technicians. The bounce, while welcome after a 25% collapse on July 14 that wiped out roughly $67 billion in market capitalization, looks more like a dead-cat spring than the start of a sustained turnaround.
The scale of the damage is hard to overstate. IBM’s preliminary second-quarter numbers landed so far below expectations that the stock suffered its worst session since 1968 — eclipsing even the 23.7% rout of Black Monday in October 1987. Revenue crept up just 1% to $17.2 billion, missing the consensus estimate of roughly $17.85 billion, while adjusted earnings per share of $2.93 fell short of the $3.01 analysts had penciled in. The full quarterly report, released the following week, confirmed the picture: the infrastructure segment slumped 7%, with mainframe Z-series sales plunging 42%.
CEO Arvind Krishna attributed the mainframe collapse to customers diverting budgets toward AI hardware, with price increases of 15% to 30% on AI components further delaying mainframe purchases. CFO Kavanaugh noted that every dollar of mainframe hardware typically generates about three times that amount in software revenue, explaining why the delays rippled through other segments. Krishna added that roughly 30% of the postponed deals had been signed in the three weeks since the preliminary release, and he expects 75% to close by year-end.
A Bounce With Technical Legs, But Not Much More
The recovery that began late last week has a mechanical explanation. The relative strength index had fallen to 35.4, deep in oversold territory, and the stock had lost nearly 19% over 30 days. That created ample room for a countermove on even modestly reassuring signals. Friday’s gain of 3.63% to €188.34 in German trading — a close match to the €188.38 close — fits the pattern of a classic technical bounce.
Should investors sell immediately? Or is it worth buying IBM?
Yet the stock remains nearly 20% below its 200-day moving average, and annualized volatility of roughly 85% means sentiment can swing violently in either direction. The 52-week high of €292.85, reached in early June, still sits about 35.7% above current levels. For the bounce to become something more, IBM would need to reclaim and hold its 50- and 200-day moving averages as support — a hurdle that looks distant.
Analyst Targets Are Catching Up to Reality
The analyst community has been scrambling to adjust. Bernstein slashed its price target from $280 to $230 and downgraded the stock to Market Perform, citing the delays in mainframe and transaction-processing deals. Susquehanna cut its target from $303 to $225 while maintaining a Neutral rating; analyst James Friedman acknowledged many positive aspects but warned that guidance might still be interpreted too conservatively. Citigroup lowered its target from $255 to $245 but kept a Buy rating.
The consensus still points to a moderate Buy with an average target of $265.40, though the range is wide — from $191 to $375. That average, however, was set before the full guidance cut and is likely to drift lower in coming days. The average target in euros of €231.11 implies upside of about 22.7%, but that figure too is stale.
Traders noted a sharp increase in call option demand on Friday, suggesting some market participants are betting on further recovery. But the underlying fundamentals remain fragile. IBM lowered its 2026 revenue growth forecast to 4% to 5% in constant currency, down from the previous outlook of more than 5%, while maintaining its expectation for a $1 billion improvement in free cash flow.
Software Shines, But Can It Compensate?
Within the disappointing headline numbers, there are genuine bright spots. Software revenue rose 5%, with Red Hat growing 11% and the data business advancing 19%. Consulting held steady at $5.3 billion. These are the figures that optimists point to as evidence that IBM’s transformation is still on track.
The problem is scale. The infrastructure business — including the flagship mainframe line — continues to exert significant downward pressure. The chip shortage in the memory segment, which is driving customers toward AI hardware at the expense of traditional IBM products, shows no signs of quick resolution. Krishna’s claim that 75% of delayed deals will close by year-end is the single most important data point for the stock’s trajectory. If that materializes, the current bounce could gain traction. If not, the record rout may prove to have been just the beginning.
IBM at a turning point? This analysis reveals what investors need to know now.
A Quantum Bet for the Long Haul
Amid the near-term turmoil, IBM is pushing ahead with its long-term strategy. The company agreed to acquire HRL Laboratories, a research lab previously owned by Boeing and General Motors that specializes in silicon-spin qubits and quantum sensing. The deal is expected to close in the third quarter of 2026 and is part of a planned $10 billion investment over five years in quantum technology, with the goal of building a fault-tolerant quantum computer by 2029. In Albany, New York, IBM is building the Anderon quantum foundry, funded equally by the U.S. Department of Commerce and IBM itself.
These are multi-year bets that offer little comfort to shareholders nursing losses from the worst trading day in the company’s history. The law firm Bronstein, Gewirtz & Grossman has announced an investigation into potential claims by IBM shareholders following the 24.6% drop in early trading after the preliminary earnings release, though no lawsuit has been filed.
For now, the stock’s fate hinges on a single question: were those second-quarter delays merely timing issues, or are customers permanently shifting their spending away from IBM’s core products? The answer will determine whether Friday’s bounce is the start of a recovery or just a pause before the next leg down.
Ad
IBM Stock: New Analysis - 25 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
